APLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Applied Therapeutics, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Class Definition - The lawsuit seeks damages for all individuals and entities that purchased or acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024 [2]. Case Details - The Complaint alleges that during the class period, the defendants made false or misleading statements and failed to disclose critical information regarding the New Drug Application (NDA) for govorestat, including deficiencies that would prevent FDA approval and insufficient clinical data to demonstrate efficacy or safety [3]. Next Steps - Investors who suffered losses in Applied Therapeutics have until February 18, 2025, to request to be appointed as lead plaintiff in the case [4]. Cost Structure - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if the case is successful [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm that has recovered hundreds of millions of dollars for investors in securities fraud class actions [6].